MDxHealth SA (NASDAQ:MDXH) Given Consensus Rating of “Moderate Buy” by Analysts

MDxHealth SA (NASDAQ:MDXH) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.6250.

Several research analysts have weighed in on the company. BTIG Research lowered their price target on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th.

Institutional Investors Weigh In On MDxHealth

Several hedge funds have recently added to or reduced their stakes in MDXH. Intesa Sanpaolo Wealth Management acquired a new stake in MDxHealth during the 4th quarter valued at $36,000. Lido Advisors LLC acquired a new stake in MDxHealth during the 3rd quarter valued at $48,000. GSA Capital Partners LLP acquired a new stake in MDxHealth during the 3rd quarter valued at $48,000. Squarepoint Ops LLC acquired a new stake in MDxHealth during the 4th quarter valued at $51,000. Finally, Jefferies Financial Group Inc. acquired a new stake in MDxHealth during the 3rd quarter valued at $53,000.

MDxHealth Stock Down 3.2%

NASDAQ MDXH opened at $0.45 on Friday. The company has a market capitalization of $22.50 million, a PE ratio of -0.70 and a beta of 1.36. The firm’s 50 day moving average is $1.20 and its 200-day moving average is $2.54. MDxHealth has a 12-month low of $0.45 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. As a group, sell-side analysts expect that MDxHealth will post -0.6 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.